November 2018 tender notification

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016, and the 2017/18 Invitation to Tender, dated 2 November 2017.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link)  and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of subsidy change

Sole Subsidised Supply date

Potassium Iodate

Tab 253 mcg (150 mcg elemental iodine);
90 tablet bottle pack

$4.69

$4.69

NeuroTabs
(AFT)

1 January 2019

1 April 2019

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Potassium Iodate

Tab 253 mcg (150 mcg elemental iodine);
90 tablet bottle pack

$4.69

$4.69

NeuroTabs
(AFT)

1%

1 January 2019

1 March 2019

2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand (Supplier)

Date of listing

Date of reference pricing of other listed brands

Sole Subsidised Supply date

Brand (Supplier) affected by reference pricing and delisting

Baclofen

Inj 2 mg per ml, 5 ml ampoule;
5 glass ampoule

$209.29 per 1 ampoule

$372.98

Medsurge
(Medsurge Healthcare)

1 February 2019

1 April 2019

1 July 2019

Lioresal Intrathecal
(Novartis)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Irinotecan hydrochloride1

Inj 20 mg per ml, 5 ml vial, 1 vial pack

$17.80

$71.44

Irinotecan Actavis 100
(Teva Pharma New Zealand Ltd)

1%

1 February 2019

1 April 2019

1 The price and subsidy of irinotecan hydrochloride inj 20 mg per ml, 5 ml vial in Section B of the Pharmaceutical Schedule will also be amended from 1 February 2019.  The subsidy for irinotecan hydrochloride inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Schedule will change from $0.19 per 1 mg to $0.75 per 1 mg from 1 April 2019. 

5. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Brand (Supplier) affected by delisting

Baclofen

Inj 2 mg per ml, 5 ml ampoule;
5 glass ampoule

$209.29 per 1 ampoule

$372.98

Medsurge
(Medsurge Healthcare)

1%

1 February 2019

1 April 2019

Lioresal Intrathecal
(Novartis)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2017/18 Invitation to Tender, dated 2 November 2017

2017/18 Invitation to Tender

Chemical name

Line item

Baclofen

Inj 0.05 mg per ml, 1 ml ampoule

Irinotecan

Inj 20 mg per ml, 2ml ampoule

For products included in the 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.